Cargando…
GMOs in animal agriculture: time to consider both costs and benefits in regulatory evaluations
In 2012, genetically engineered (GE) crops were grown by 17.3 million farmers on over 170 million hectares. Over 70% of harvested GE biomass is fed to food producing animals, making them the major consumers of GE crops for the past 15 plus years. Prior to commercialization, GE crops go through an ex...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015968/ https://www.ncbi.nlm.nih.gov/pubmed/24066781 http://dx.doi.org/10.1186/2049-1891-4-37 |
_version_ | 1782315438004240384 |
---|---|
author | Van Eenennaam, Alison L |
author_facet | Van Eenennaam, Alison L |
author_sort | Van Eenennaam, Alison L |
collection | PubMed |
description | In 2012, genetically engineered (GE) crops were grown by 17.3 million farmers on over 170 million hectares. Over 70% of harvested GE biomass is fed to food producing animals, making them the major consumers of GE crops for the past 15 plus years. Prior to commercialization, GE crops go through an extensive regulatory evaluation. Over one hundred regulatory submissions have shown compositional equivalence, and comparable levels of safety, between GE crops and their conventional counterparts. One component of regulatory compliance is whole GE food/feed animal feeding studies. Both regulatory studies and independent peer-reviewed studies have shown that GE crops can be safely used in animal feed, and rDNA fragments have never been detected in products (e.g. milk, meat, eggs) derived from animals that consumed GE feed. Despite the fact that the scientific weight of evidence from these hundreds of studies have not revealed unique risks associated with GE feed, some groups are calling for more animal feeding studies, including long-term rodent studies and studies in target livestock species for the approval of GE crops. It is an opportune time to review the results of such studies as have been done to date to evaluate the value of the additional information obtained. Requiring long-term and target animal feeding studies would sharply increase regulatory compliance costs and prolong the regulatory process associated with the commercialization of GE crops. Such costs may impede the development of feed crops with enhanced nutritional characteristics and durability, particularly in the local varieties in small and poor developing countries. More generally it is time for regulatory evaluations to more explicitly consider both the reasonable and unique risks and benefits associated with the use of both GE plants and animals in agricultural systems, and weigh them against those associated with existing systems, and those of regulatory inaction. This would represent a shift away from a GE evaluation process that currently focuses only on risk assessment and identifying ever diminishing marginal hazards, to a regulatory approach that more objectively evaluates and communicates the likely impact of approving a new GE plant or animal on agricultural production systems. |
format | Online Article Text |
id | pubmed-4015968 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-40159682014-05-10 GMOs in animal agriculture: time to consider both costs and benefits in regulatory evaluations Van Eenennaam, Alison L J Anim Sci Biotechnol Review In 2012, genetically engineered (GE) crops were grown by 17.3 million farmers on over 170 million hectares. Over 70% of harvested GE biomass is fed to food producing animals, making them the major consumers of GE crops for the past 15 plus years. Prior to commercialization, GE crops go through an extensive regulatory evaluation. Over one hundred regulatory submissions have shown compositional equivalence, and comparable levels of safety, between GE crops and their conventional counterparts. One component of regulatory compliance is whole GE food/feed animal feeding studies. Both regulatory studies and independent peer-reviewed studies have shown that GE crops can be safely used in animal feed, and rDNA fragments have never been detected in products (e.g. milk, meat, eggs) derived from animals that consumed GE feed. Despite the fact that the scientific weight of evidence from these hundreds of studies have not revealed unique risks associated with GE feed, some groups are calling for more animal feeding studies, including long-term rodent studies and studies in target livestock species for the approval of GE crops. It is an opportune time to review the results of such studies as have been done to date to evaluate the value of the additional information obtained. Requiring long-term and target animal feeding studies would sharply increase regulatory compliance costs and prolong the regulatory process associated with the commercialization of GE crops. Such costs may impede the development of feed crops with enhanced nutritional characteristics and durability, particularly in the local varieties in small and poor developing countries. More generally it is time for regulatory evaluations to more explicitly consider both the reasonable and unique risks and benefits associated with the use of both GE plants and animals in agricultural systems, and weigh them against those associated with existing systems, and those of regulatory inaction. This would represent a shift away from a GE evaluation process that currently focuses only on risk assessment and identifying ever diminishing marginal hazards, to a regulatory approach that more objectively evaluates and communicates the likely impact of approving a new GE plant or animal on agricultural production systems. BioMed Central 2013-09-25 /pmc/articles/PMC4015968/ /pubmed/24066781 http://dx.doi.org/10.1186/2049-1891-4-37 Text en Copyright © 2013 Van Eenennaam; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Van Eenennaam, Alison L GMOs in animal agriculture: time to consider both costs and benefits in regulatory evaluations |
title | GMOs in animal agriculture: time to consider both costs and benefits in regulatory evaluations |
title_full | GMOs in animal agriculture: time to consider both costs and benefits in regulatory evaluations |
title_fullStr | GMOs in animal agriculture: time to consider both costs and benefits in regulatory evaluations |
title_full_unstemmed | GMOs in animal agriculture: time to consider both costs and benefits in regulatory evaluations |
title_short | GMOs in animal agriculture: time to consider both costs and benefits in regulatory evaluations |
title_sort | gmos in animal agriculture: time to consider both costs and benefits in regulatory evaluations |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015968/ https://www.ncbi.nlm.nih.gov/pubmed/24066781 http://dx.doi.org/10.1186/2049-1891-4-37 |
work_keys_str_mv | AT vaneenennaamalisonl gmosinanimalagriculturetimetoconsiderbothcostsandbenefitsinregulatoryevaluations |